Trial Profile
Effect of Dupilumab on Sleep Apnea Severity in Patients With Chronic Rhinosinusitis
Status:
Discontinued
Phase of Trial:
Phase 0
Latest Information Update: 06 Oct 2022
Price :
$35
*
At a glance
- Drugs Dupilumab (Primary)
- Indications Rhinosinusitis
- Focus Therapeutic Use
- 04 Oct 2022 Status changed from recruiting to discontinued, according to clinicalTrials.gov: US National Institutes of Health.
- 09 Jul 2019 Status changed from not yet recruiting to recruiting.
- 22 Sep 2018 New trial record